Company Profile

KAINOS Laboratories, Inc. is pricipally engaged in researching, developing, manufacturing and selling clinical diagnostic reagents, including biochemical diagnostic reagents such as renal function related reagents and automatic biochemical analytical reagents, immune serological test reagents such as transfusion-related reagents, allergy-related reagents, cancer marker related reagents, and other reagents.

Employees

133

Sector

Medical Equipment, Supplies & Distribution

More about the company

Delayed Japan Exchange Other stock markets 14:30:00 10/06/2026 HKT			5-day change	1st Jan Change
2,268.00 ^JPY	0.00%		0.00%	+78.44%

04-22	Kainos Laboratories Inc - to retire treasury shares worth 3.6% of outstanding stock on Jun 12	RE
03-25	Denka Company Limited completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. from a group of shareholders.	CI

04-22	Kainos Laboratories Inc - to retire treasury shares worth 3.6% of outstanding stock on Jun 12	RE
03-25	Denka Company Limited completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. from a group of shareholders.	CI
02-09	Denka Company Limited proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. from a group of shareholders for ¥7.9 billion.	CI
02-09	Denka Unit Launches Tender Offer for Kainos Laboratories	MT
02-06	Denka Co Ltd - Will launch tender offer for Kainos shares	RE
18/12/24	Italian stationery maker FILA cuts stake in listed Indian unit DOMS	RE
14/03/22	KAINOS Laboratories, Inc. announced that it has received ¥250.47 million in funding from Sysmex Corporation	CI
25/02/22	KAINOS Laboratories, Inc. announced that it expects to receive ¥250.47 million in funding from Sysmex Corporation	CI
26/11/21	Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2021.	CI
26/11/21	KAINOS Laboratories, Inc.'s Equity Buyback announced on November 25, 2021, has closed with 150,000 shares, representing 3.66% for ¥158.1 million.	CI
25/11/21	KAINOS Laboratories, Inc. announces an Equity Buyback for 150,000 shares, for ¥158.1 million.	CI
25/11/21	KAINOS Laboratories, Inc. authorizes a Buyback Plan.	CI
26/11/20	Tranche Update on KAINOS Laboratories, Inc.'s Equity Buyback Plan announced on November 25, 2020.	CI

Current month	+0.18%
1 month	-0.22%
3 months	+0.58%
6 months	+80.72%
Current year	+78.44%

1 month	2,263	2,277
Current year	1,257	2,284
1 year	1,204	2,284
3 years	1,005	2,284
5 years	929	2,284
10 years	488	2,284

KAINOS Laboratories, Inc. Stock

Stocks

4556

JP3205650009

Medical Equipment, Supplies & Distribution

Chart: KAINOS Laboratories, Inc.

Latest news : KAINOS Laboratories, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: KAINOS Laboratories, Inc.

Diagnostic & Testing Substances

Company Profile

Manager	Title	Age	Since
Yukihiro Nagatsu PSD	President	66	01/04/2022
Tsukasa Hayashi ADM	Chief Administrative Officer	64	01/06/2016
Nobuaki Nakano PRN	Corporate Officer/Principal	62	01/07/2024

Director	Title	Age	Since
Yukihiro Nagatsu BRD	Director/Board Member	66	01/06/2014
Tsukasa Hayashi BRD	Director/Board Member	64	01/06/2014
Kenji Kikuchi BRD	Director/Board Member	74	01/06/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KAINOS LABORATORIES, INC.	0.00%	0.00%	-	-	62.52M
GUARDANT HEALTH, INC.	+3.03%	+19.34%	+202.28%	+323.64%	19.79B
BIOMÉRIEUX	-1.96%	+3.79%	-41.30%	-26.63%	9.59B
LANTHEUS HOLDINGS, INC.	-0.20%	+3.18%	+34.47%	+32.10%	7.15B
CARIS LIFE SCIENCES, INC.	-0.97%	+5.83%	-31.67%	-	5.23B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+1.44%	+1.18%	-23.20%	-26.72%	4.9B
10X GENOMICS, INC.	+1.09%	+12.78%	+216.71%	-34.48%	4.67B
DIASORIN S.P.A.	0.00%	+6.87%	-23.99%	-24.48%	4.13B
ANDON HEALTH CO., LTD.	+0.50%	-8.30%	+85.64%	+91.76%	4.09B
AUTOBIO DIAGNOSTICS CO., LTD.	+4.11%	-0.96%	-19.95%	-41.98%	2.41B
Average	+0.70%	+4.14%	+44.33%	+36.65%	6.88B
Weighted average by Cap.	+0.95%	+8.12%	+77.29%	+110.36%